These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 31921686)

  • 21. Exploring the educational needs for severe immune-related adverse events of PD-1/PD-L1 inhibitors in advanced lung cancer: A single-center observational study.
    Aso S; Kawamura N; Yanagida H; Nakajima K; Ishikawa H; Omori S; Murakami H; Takahashi T; Naito T
    Asia Pac J Oncol Nurs; 2022 Aug; 9(8):100076. PubMed ID: 36065289
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The incidence and relative risk of PD-1/PD-L1 inhibitors-related colitis in non-small cell lung cancer: A meta-analysis of randomized controlled trials.
    Lin LL; Lin GF; Luo Q; Chen XQ
    Int Immunopharmacol; 2019 Dec; 77():105975. PubMed ID: 31704288
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature.
    Pillai RN; Behera M; Owonikoko TK; Kamphorst AO; Pakkala S; Belani CP; Khuri FR; Ahmed R; Ramalingam SS
    Cancer; 2018 Jan; 124(2):271-277. PubMed ID: 28960263
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study.
    Delanoy N; Michot JM; Comont T; Kramkimel N; Lazarovici J; Dupont R; Champiat S; Chahine C; Robert C; Herbaux C; Besse B; Guillemin A; Mateus C; Pautier P; Saïag P; Madonna E; Maerevoet M; Bout JC; Leduc C; Biscay P; Quere G; Nardin C; Ebbo M; Albigès L; Marret G; Levrat V; Dujon C; Vargaftig J; Laghouati S; Croisille L; Voisin AL; Godeau B; Massard C; Ribrag V; Marabelle A; Michel M; Lambotte O
    Lancet Haematol; 2019 Jan; 6(1):e48-e57. PubMed ID: 30528137
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report.
    Li H; Ma W; Yoneda KY; Moore EH; Zhang Y; Pu LL; Frampton GM; Molmen M; Stephens PJ; Li T
    J Hematol Oncol; 2017 Feb; 10(1):64. PubMed ID: 28245875
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune checkpoint inhibitor-related pneumonitis with atypical radiologic features in a patient with anti-aminoacyl-tRNA synthetase antibody.
    Ichihara S; Ogino H; Yoneda H; Haji K; Kagawa K; Murakami K; Mima M; Aoi Y; Mitsuhashi A; Tsukazaki Y; Yabuki Y; Ozaki R; Sato S; Nokihara H; Nishioka Y
    Respir Med Case Rep; 2023; 41():101797. PubMed ID: 36583061
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Late-onset programmed cell death protein-1 inhibitor-induced pneumonitis after cessation of nivolumab or pembrolizumab in patients with advanced non-small cell lung cancer: a case series.
    Kimura H; Sone T; Araya T; Murata A; Yamamura K; Ohkura N; Hara J; Abo M; Kasahara K
    Transl Lung Cancer Res; 2021 Mar; 10(3):1576-1581. PubMed ID: 33889531
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recurrent Pneumonitis in Patients with Melanoma Treated with Immune Checkpoint Inhibitors.
    Asher N; Marom EM; Ben-Betzalel G; Baruch EN; Steinberg-Silman Y; Schachter J; Shapira-Frommer R; Markel G
    Oncologist; 2019 May; 24(5):640-647. PubMed ID: 30777894
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial.
    Loi S; Giobbie-Hurder A; Gombos A; Bachelot T; Hui R; Curigliano G; Campone M; Biganzoli L; Bonnefoi H; Jerusalem G; Bartsch R; Rabaglio-Poretti M; Kammler R; Maibach R; Smyth MJ; Di Leo A; Colleoni M; Viale G; Regan MM; André F;
    Lancet Oncol; 2019 Mar; 20(3):371-382. PubMed ID: 30765258
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lethal Immune-Related Pneumonitis after Durvalumab Therapy for Small Cell Lung Cancer: A First Case in China.
    Li Q; Liu M; Liu Y; Shi F; Yuan S; Di G; Jin H; Shi Y; Zhang W; Yang Z
    Case Rep Oncol; 2024; 17(1):673-680. PubMed ID: 39015639
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety of thoracic radiotherapy after PD-(L)1 inhibitor treatment in patients with lung cancer.
    Chen Y; Liu X; Huang Z; Zhao K; Wang Y; Ren F; Yu J; Meng X
    Cancer Med; 2021 Dec; 10(23):8518-8529. PubMed ID: 34664788
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immune-related adverse event profile of combination treatment of PD-(L)1 checkpoint inhibitors and bevacizumab in non-small cell lung cancer patients: data from the FDA adverse event reporting system.
    Bai S; Tian T; Pacheco JM; Tachihara M; Hu P; Zhang J
    Transl Lung Cancer Res; 2021 Jun; 10(6):2614-2624. PubMed ID: 34295666
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and Efficacy of PD-1/PD-L1 Inhibitors in Treatment-Naive and Chemotherapy-Refractory Patients With Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Khunger M; Jain P; Rakshit S; Pasupuleti V; Hernandez AV; Stevenson J; Pennell NA; Velcheti V
    Clin Lung Cancer; 2018 May; 19(3):e335-e348. PubMed ID: 29433902
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sex Differences in Tolerability to Anti-Programmed Cell Death Protein 1 Therapy in Patients with Metastatic Melanoma and Non-Small Cell Lung Cancer: Are We All Equal?
    Duma N; Abdel-Ghani A; Yadav S; Hoversten KP; Reed CT; Sitek AN; Enninga EAL; Paludo J; Aguilera JV; Leventakos K; Lou Y; Kottschade LA; Dong H; Mansfield AS; Manochakian R; Adjei AA; Dronca RS
    Oncologist; 2019 Nov; 24(11):e1148-e1155. PubMed ID: 31036771
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PD-1 checkpoint inhibition: Toxicities and management.
    Hahn AW; Gill DM; Agarwal N; Maughan BL
    Urol Oncol; 2017 Dec; 35(12):701-707. PubMed ID: 28889921
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy.
    Shiuan E; Beckermann KE; Ozgun A; Kelly C; McKean M; McQuade J; Thompson MA; Puzanov I; Greer JP; Rapisuwon S; Postow M; Davies MA; Eroglu Z; Johnson D
    J Immunother Cancer; 2017; 5():8. PubMed ID: 28239462
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment with a programmed cell death-1-specific antibody has little effect on afatinib- and naphthalene-induced acute pneumonitis in mice.
    Hamada N; Yanagihara T; Suzuki K; Ogata-Suetsugu S; Harada E; Mikumo H; Arimura-Omori M; Nakanishi Y
    Biochem Biophys Res Commun; 2017 Sep; 491(3):656-661. PubMed ID: 28756224
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radiologic and autopsy findings in a case of fatal immune checkpoint inhibitor-associated pneumonitis.
    Shea M; Rangachari D; Hallowell RW; Hollie NI; Costa DB; VanderLaan PA
    Cancer Treat Res Commun; 2018; 15():17-20. PubMed ID: 30207283
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.